Author Archives: pancreatica
Modified Irinotecan for Multi-drug Treatment of Pancreatic Cancer – an Update
More than a year ago (10/22/15), the U.S. Food and Drug Administration approved a modified form of the FOLFIRINOX regimen as a second line treatment for patients with metastatic pancreatic cancer (ductal adenocarcinoma of the pancreas) whose gemcitabine-based therapy had failed. We reported this development Here. The modified FDA-approved regimen was different from the “standard” […]
Inexpensive Urine Protein Array for the Early Diagnosis of Pancreatic Cancer
At one point several years back, we at Pancreatica looked at the number of studies in pancreatic cancer (ductal adenocarcinoma of the pancreas) that dealt with early detection versus those aimed at treatment. We found that less than 3% were aimed at the detection of pancreatic cancer. This rate has since increased, but when interesting […]
2016 ASCO Practice Guidelines for Advanced Pancreatic Cancer
2016 ASCO PRACTICE GUIDELINES FOR ADVANCED ADENOCARCINOMA OF THE PANCREAS Davendra P.S. Sohal, Pamela B. Mangu, Alok A. Khorana, Manish A. Shah, Philip A. Philip, Eileen M. O’Reilly, Hope E. Uronis, Ramesh K. Ramanathan, Christopher H. Crane, Anitra Engebretson, Joseph T. Ruggiero, Mehmet S. Copur, Michelle Lau, Susan Urba and Daniel Laheru Abstract Purpose: […]
MRI Screening Protocol for Pancreatic Cancer as Surveillance for High Risk Family Members
About 10% of those diagnosed with pancreatic cancer (ductal adenocarcinoma of the pancreas) are found to have a reasonably strong pancreatic cancer family history or that of another genetic complex or syndrome which tends to include pancreatic cancer. Consequently, many family members often ask us or their medical teams what their risks are, and what […]
“Modified” FOLFIRINOX Regimen Approved by FDA for 2nd Line Treatment of Pancreatic Cancer
On the 22nd of October, 2015, the U.S. Food and Drug Administration approved a new combination therapy that includes the drug Onivyde for patients with metastatic pancreatic cancer (ductal adenocarcinoma of the pancreas) who had earlier been treated until progression of disease while on gemcitabine or a gemcitabine-based regimen. Onivyde is liposomal irinotecan, a topoisomerase I […]